{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:11:09Z","timestamp":1790179869970,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Maruho Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Amenamevir is a potent helicase\u2013primase inhibitor and a novel class of antiviral agent other than nucleoside compounds, such as aciclovir, valaciclovir and famciclovir. This study is the first randomized, double\u2010blind, valaciclovir\u2010controlled phase 3 study to evaluate the efficacy and safety of amenamevir in Japanese patients with herpes zoster when treated within 72 h after onset of rash. A total of 751 patients were randomly assigned to receive either amenamevir 400 mg or 200 mg p.o. once daily or valaciclovir 1000 mg three times daily (daily dose, 3000 mg) for 7 days. The primary efficacy end\u2010point was the proportion of cessation of new lesion formation by day 4 (\u201cday 4 cessation proportion\u201d). The day 4 cessation proportions for amenamevir 400 and 200 mg and valaciclovir were 81.1% (197\/243), 69.6% (172\/247) and 75.1% (184\/245), respectively. Non\u2010inferiority of amenamevir 400 mg to valaciclovir was confirmed by a closed testing procedure. Days to cessation of new lesion formation, complete crusting, healing, pain resolution and virus disappearance were evaluated as secondary end\u2010points. No significant differences were observed in any of the treatment groups. Amenamevir 400 and 200 mg were well tolerated as well as valaciclovir. The proportions of patients who experienced drug\u2010related adverse events were 10.0% (25\/249), 10.7% (27\/252) and 12.0% (30\/249) with amenamevir 400 and 200 mg and valaciclovir, respectively. In conclusion, amenamevir 400 mg appears to be effective and well tolerated for treatment of herpes zoster in immunocompetent Japanese patients.<\/jats:p>","DOI":"10.1111\/1346-8138.13948","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:43:24Z","timestamp":1499301804000},"page":"1219-1227","source":"Crossref","is-referenced-by-count":73,"title":["Amenamevir, a novel helicase\u2013primase inhibitor, for treatment of herpes zoster: A randomized, double\u2010blind, valaciclovir\u2010controlled phase 3 study"],"prefix":"10.1111","volume":"44","author":[{"given":"Makoto","family":"Kawashima","sequence":"first","affiliation":[{"name":"Department of Dermatology Tokyo Women's Medical University Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Sapporo Skin Clinic Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Honda","sequence":"additional","affiliation":[{"name":"Dr Mariko Skin and Dermatology Clinic Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Dermatology Aichi Medical University Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juichiro","family":"Nakayama","sequence":"additional","affiliation":[{"name":"General Medical Research Center Fukuoka University Faculty of Medicine  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Dermatology Fukuoka University Faculty of Medicine Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kato","sequence":"additional","affiliation":[{"name":"Maruho Co., Ltd Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9939-8391","authenticated-orcid":false,"given":"Tsuneo","family":"Katsuramaki","sequence":"additional","affiliation":[{"name":"Maruho Co., Ltd Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.9.3.361"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1302674"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw119"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1403062"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.4065\/82.11.1341"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1201-9712(07)60021-6"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01209.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20140210"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/510206"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/12.suppl_B.9"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(02)00263-9"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-6701(96)90010-9"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2412"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.1.76"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06620-11"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-67-9-1759"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0402-392"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.7.2186"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi9010144"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq198"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780091208"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2307\/2532800"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00133-12"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis019"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2011"},{"key":"e_1_2_7_28_1","first-page":"2867","article-title":"Phase III study of valaciclovir hydrochloride tablets in patients with herpes zoster \u2013 double\u2010blind comparative study with aciclovir tablets","volume":"14","author":"Niimura M","year":"1998","journal-title":"J Clin Ther Med"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/120347540100500508"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.2.341"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1086\/514271"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(10)70005-6"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80109-0"},{"issue":"27","key":"e_1_2_7_34_1","first-page":"115","article-title":"Adherence to antiviral therapy in HIV or HBV\u2010infected patients","volume":"70","author":"W\u00f3jcik K","year":"2016","journal-title":"Przegl Epidemiol"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.13948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.13948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T02:10:31Z","timestamp":1695521431000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.13948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/1346-8138.13948"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.13948","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727782407.793534628","asserted-by":"object"}]},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,5]]}}}